Article
Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
7 Dec 2022
Abstract excerpt
Ovarian cancer is among the most common malignant tumors in gynecology and is characterized by insidious onset, poor differentiation, high malignancy, and a high recurrence rate. Numerous studies have shown that poly ADP-ribose polymerase (PARP) inhibitors can improve progression-free survival (PFS) in patients with BRCA-mutated ovarian cancer. With the widespread use of BRCA mutation and PARP inhibitor (PARPi)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
